Viatris(NASDAQ) VTRS

Viatris Inc. NASDAQ:VTRS makes and sells medicines to people worldwide. It helps patients manage health issues with well-known drug brands. The company provides affordable generic versions of common prescriptions.

Medicines for Every Stage

• Iconic Brands: Established prescription medications for chronic conditions including Lipitor, Norvasc, and the EpiPen auto-injector for allergic reactions.
• Generics and Complex Generics: Lower-cost versions of off-patent medicines including Wixela Inhub and various oral solid doses.
• Biosimilars: Advanced biologic treatments highly similar to existing products used in oncology, immunology, and dermatology.
• Active Pharmaceutical Ingredients: Essential raw materials used to manufacture drugs including antibacterials, antivirals, and central nervous system agents.

Reshaping the Global Business

• Initiated a strategic review in 2025 to create a more efficient and focused organization.
• Committed to a restructuring program in February 2026 involving a global workforce reduction of approximately 10%.
• Divested an equity stake in Biocon Biologics for $815 million in total consideration during the first quarter of 2026.
• Authorized a $1 billion increase to the existing share repurchase program in February 2024.

Science at a Global Scale

Viatris operates 27 manufacturing and packaging sites that distribute approximately 1,300 approved molecules to more than 165 countries. The company utilizes a global supply chain and scientific expertise to address both infectious and noncommunicable diseases.

A Look at the Numbers

• Total revenues rose 5% year over year to $3.76 billion for the three months ended June 30, 2026.
• Developed Markets net sales reached $2.19 billion for the quarter ended June 30, 2026, with $1.31 billion generated in Europe.
• Greater China net sales increased 21% year over year to $713.8 million during the second quarter of 2026.
• Net cash provided by operating activities totaled $770.1 million for the six-month period ended June 30, 2026.

Viatris in Evolution

Viatris is transitioning into a leaner organization by divesting noncore assets and restructuring its global operations. The company balances a broad portfolio of established brands with generic manufacturing to serve patients worldwide.